Organon to Release Third Quarter 2024 Results
Organon (NYSE: OGN), a prominent global healthcare company dedicated to women's health, has announced the upcoming release of its third quarter 2024 financial results. The results are scheduled to be made public on October 31, 2024, just before a live webcast and conference call at 8:30 a.m. EDT, allowing stakeholders to gain valuable insights into the company's financial performance.
Understanding IPR&D and Financial Impact
For the third quarter of 2024, Organon anticipates a notable milestone expense of $51 million. This amount translates into an estimated impact of around $0.16 on both GAAP and non-GAAP earnings per share. Of this expenditure, it is expected that $50 million will be associated with a denosumab biosimilar candidate, under an ongoing license agreement with Shanghai Henlius Biotech, Inc.
Milestone Expectations
It's important to note that Organon has opted not to forecast IPR&D (in-process research and development) or related milestones, given the inherent uncertainties associated with predicting the timing of these developments. Consequently, the aforementioned milestones, along with any future IPR&D expenses, are not included in the financial guidance provided on August 6, 2024. As the quarter's financial results are still pending finalization, they remain subject to standard closing procedures. This introduces a degree of variability, making it necessary for stakeholders to consider that actual results may differ from the preliminary estimates.
Accessing the Webcast for Financial Results
Those interested in accessing the live call can do so via the Organon website, where the webcast will be available. A recording of the event will also be provided approximately two hours after the conclusion of the live discussion, ensuring that interested parties can catch up on the insights shared.
Registration for Participants
Institutional investors and analysts who wish to participate in this event need to register in advance. Upon registration, they will receive a confirmation email containing details for joining the conference call. This includes important information such as dial-in instructions, a unique passcode, and a registrant ID, allowing them to join the call directly without waiting for an operator.
About Organon and Its Mission
Organon is committed to enhancing women’s health by offering over 60 medicines and products that cater to various needs. The company’s expansive portfolio features biosimilars along with a broad range of established pharmaceuticals across diverse therapeutic areas. Focused on fostering growth in women’s health, Organon invests in innovative solutions and research while actively seeking collaborations with biopharmaceutical partners.
Global Reach and Workforce
With an extensive geographical footprint and impressive commercial capabilities, Organon employs approximately 10,000 people globally, operating with its headquarters in Jersey City, New Jersey. Its mission is central to its operations, striving to improve health outcomes for women throughout their lives.
Frequently Asked Questions
1. When will Organon announce its third quarter results?
Organon is set to announce its third quarter 2024 financial results on October 31, 2024.
2. What is the expected financial impact for the third quarter?
The company anticipates recognizing a milestone expense of $51 million, impacting earnings per share by approximately $0.16.
3. Will IPR&D expenses be included in the financial guidance?
No, IPR&D expenses and milestones are not included in the financial guidance due to uncertainty.
4. How can I access the webcast?
The live webcast of the conference call can be accessed on the Organon website.
5. What is Organon's primary mission?
Organon is focused on improving women's health through the provision of medicines and innovative solutions.
